Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients.
Matakidou, Athena;
El Galta, Rachid;
Webb, Emily L;
Rudd, Matthew F;
Bridle, Helen;
Eisen, Tim;
Houlston, Richard S;
GELCAPS Consortium;
(2007)
Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients.
Lung cancer (Amsterdam, Netherlands), 57 (2).
pp. 207-212.
ISSN 0169-5002
DOI: https://doi.org/10.1016/j.lungcan.2007.02.021
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
The prognostic significance of the Arg72Pro polymorphism of the p53 tumour suppressor gene in cancer is controversial. To determine whether Arg72Pro is a marker for lung cancer prognosis we genotyped 619 female lung cancer patients with incident disease and examined the relationship between genotype and overall survival (OS). Nonparametric tests provided no evidence for a relationship between SNP genotype and OS (P-values 0.131, 0.161, and 0.156 for log rank, Wilcoxon and Fleming-Harrington test statistics, respectively). Under the Cox proportional hazards model the HRs associated with Arg/Pro, Pro/Pro and Pro-carrier status were: 0.98 (95%CI: 0.79-1.22), 0.76 (95%CI: 0.51-1.15) and 0.93 (95%CI: 0.76-1.15), respectively. Despite employing a comprehensive set of statistical tests including those sensitive to the detection of differences in early survival our data provide little evidence to support the tenet that the p53 Arg72Pro polymorphism is a clinically useful prognostic marker for lung cancer.
